Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Decreases By 76.1%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) saw a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 39,700 shares, a decline of 76.1% from the February 29th total of 166,100 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average trading volume of 212,600 shares, the short-interest ratio is presently 0.2 days.

Coeptis Therapeutics Price Performance

Shares of NASDAQ:COEP remained flat at $0.30 during trading on Thursday. 157,269 shares of the stock were exchanged, compared to its average volume of 219,299. Coeptis Therapeutics has a 52 week low of $0.29 and a 52 week high of $2.19. The firm has a 50 day simple moving average of $0.48 and a 200-day simple moving average of $0.83. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.55 and a quick ratio of 2.55. The company has a market cap of $10.14 million, a PE ratio of -0.35 and a beta of -0.79.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Mint Tower Capital Management B.V. acquired a new stake in Coeptis Therapeutics during the 4th quarter worth $35,000. Armistice Capital LLC grew its holdings in Coeptis Therapeutics by 59.1% during the 4th quarter. Armistice Capital LLC now owns 3,520,000 shares of the company’s stock worth $2,759,000 after acquiring an additional 1,308,000 shares during the period. Shaolin Capital Management LLC acquired a new stake in Coeptis Therapeutics during the 2nd quarter worth $70,000. Ionic Capital Management LLC acquired a new stake in Coeptis Therapeutics during the 2nd quarter worth $70,000. Finally, Geode Capital Management LLC grew its holdings in Coeptis Therapeutics by 153.1% during the 2nd quarter. Geode Capital Management LLC now owns 100,201 shares of the company’s stock worth $155,000 after acquiring an additional 60,608 shares during the period. Institutional investors own 13.88% of the company’s stock.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.